Spots Global Cancer Trial Database for su011248
Every month we try and update this database with for su011248 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Bevacizumab in Multiple Phase I Combinations | NCT00543504 | Advanced Cancer | Bevacizumab Sorafenib Erlotinib Trastuzumab Lapatinib Sunitinib Cetuximab | - | M.D. Anderson Cancer Center | |
| Bevacizumab in Multiple Phase I Combinations | NCT00543504 | Advanced Cancer | Bevacizumab Sorafenib Erlotinib Trastuzumab Lapatinib Sunitinib Cetuximab | - | M.D. Anderson Cancer Center | |
| Clinical Study of SU011248 in Subjects With High Risk Prostate Cancer Who Have Elected to Undergo Radical Prostatectomy | NCT00790595 | Prostate Cancer | SU011248 SU011248 SU011248 SU011248 SU011248 | 18 Years - 75 Years | Jonsson Comprehensive Cancer Center | |
| A Study To Assess The Safety And Efficacy Of SU11248 In Patients With Gastrointestinal Stromal Tumor(GIST) | NCT00075218 | Gastrointestina... | Placebo SU011248 | 18 Years - | Pfizer | |
| A Study of SU11248 In Patients With Metastatic Breast Cancer Who Have Failed Selected Other Therapies. | NCT00078000 | Breast Neoplasm... | SU011248 | 18 Years - | Pfizer | |
| SU011248 in Combination With Irinotecan and Cetuximab as a Second Line Regimen for Stage IV Colorectal Cancer | NCT00361244 | Colorectal Carc... | SU011248 Irinotecan Cetuximab | 18 Years - | Massachusetts General Hospital | |
| Pre-Surgical Sutent in Renal Cell Carcinoma (RCC) | NCT00715442 | Renal Cell Carc... | Sunitinib Nephrectomy | - | M.D. Anderson Cancer Center | |
| A Study To Assess The Safety And Efficacy Of SU11248 In Patients With Gastrointestinal Stromal Tumor(GIST) | NCT00075218 | Gastrointestina... | Placebo SU011248 | 18 Years - | Pfizer | |
| A Pivotal Study Of SU011248 In The Treatment Of Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma. | NCT00077974 | Carcinoma, Rena... | SU011248 | 18 Years - | Pfizer | |
| Sunitinib Malate, Hormone Ablation and Radiation Therapy in Patients With Prostate Cancer | NCT00631527 | Prostate Cancer | Leuprolide Goserelin Sunitinib Malat... Casodex Radiation Thera... | 18 Years - | M.D. Anderson Cancer Center | |
| Study Of SU011248 In Combination With Docetaxel (Taxotere) And Prednisone In Patients With Prostate Cancer | NCT00137436 | Prostatic Neopl... | Docetaxel Prednisone SU011248 | 18 Years - | Pfizer | |
| A SU011248 Expanded Access Protocol for Systemic Therapy of Patients With Metastatic Renal Cell Carcinoma Who Are Ineligible for Participation in Other SU011248 Protocols But May Derive Benefit From Treatment With SU011248 | NCT00531544 | Metastatic Rena... | SU011248 | 18 Years - 85 Years | King Faisal Specialist Hospital & Research Center | |
| SU011248 in Combination With Irinotecan and Cetuximab as a Second Line Regimen for Stage IV Colorectal Cancer | NCT00361244 | Colorectal Carc... | SU011248 Irinotecan Cetuximab | 18 Years - | Massachusetts General Hospital | |
| Study Of SU011248 In Combination With Docetaxel (Taxotere) And Prednisone In Patients With Prostate Cancer | NCT00137436 | Prostatic Neopl... | Docetaxel Prednisone SU011248 | 18 Years - | Pfizer | |
| Study Of SU011248 Versus Chemotherapy For Patients With Previously Treated Triple Receptor Negative Breast Cancer | NCT00246571 | Breast Neoplasm... | SU011248 Chemotherapy | 18 Years - | Pfizer | |
| Sunitinib Malate With Hormonal Ablation for Patients Who Will Have Prostatectomy | NCT00329043 | Prostate Cancer | LHRH Agonist Sunitinib Malat... Radical Prostat... | - | M.D. Anderson Cancer Center | |
| Sunitinib Malate With Hormonal Ablation for Patients Who Will Have Prostatectomy | NCT00329043 | Prostate Cancer | LHRH Agonist Sunitinib Malat... Radical Prostat... | - | M.D. Anderson Cancer Center | |
| SU011248 in Advanced Hepatocellular Carcinoma | NCT00361309 | Hepatocellular ... Liver Cancer | SU011248 | 18 Years - | Massachusetts General Hospital | |
| A SU011248 Expanded Access Protocol for Systemic Therapy of Patients With Metastatic Renal Cell Carcinoma Who Are Ineligible for Participation in Other SU011248 Protocols But May Derive Benefit From Treatment With SU011248 | NCT00531544 | Metastatic Rena... | SU011248 | 18 Years - 85 Years | King Faisal Specialist Hospital & Research Center | |
| Dose-Finding Study Of CP-675,206 And SU011248 In Patients With Metastatic Renal Cell Carcinoma | NCT00372853 | Carcinoma, Rena... | CP-675,206 SU011248 CP-675,206 SU011248 | 18 Years - | AstraZeneca | |
| SU011248 Versus Interferon-Alfa As First-Line Systemic Therapy For Patients With Metastatic Renal Cell Carcinoma | NCT00083889 | Carcinoma, Rena... | Interferon-alfa SU011248 | 18 Years - | Pfizer | |
| Clinical Study of SU011248 in Subjects With High Risk Prostate Cancer Who Have Elected to Undergo Radical Prostatectomy | NCT00790595 | Prostate Cancer | SU011248 SU011248 SU011248 SU011248 SU011248 | 18 Years - 75 Years | Jonsson Comprehensive Cancer Center | |
| Valproic Acid-Based 2-Agent Oral Regimens for Patients With Advanced Solid Tumor | NCT00495872 | Solid Tumors | Dasatinib Erlotinib Lapatinib Lenalidomide Sorafenib Sunitinib Valproic Acid | - | M.D. Anderson Cancer Center | |
| Bevacizumab in Multiple Phase I Combinations | NCT00543504 | Advanced Cancer | Bevacizumab Sorafenib Erlotinib Trastuzumab Lapatinib Sunitinib Cetuximab | - | M.D. Anderson Cancer Center | |
| Efficacy of SU 011248 in Head And Neck Carcinoma | NCT00408252 | Recurrent Disea... Squamous Cell H... Palliative Trea... | biopsies SU011248 | 18 Years - | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | |
| Ph I SU011248 + Irinotecan in Treatment of Pts w MG | NCT00611728 | Glioblastoma | SU011248 & Irin... | 18 Years - | Duke University | |
| SU011248 Versus Interferon-Alfa As First-Line Systemic Therapy For Patients With Metastatic Renal Cell Carcinoma | NCT00083889 | Carcinoma, Rena... | Interferon-alfa SU011248 | 18 Years - | Pfizer | |
| Valproic Acid-Based 2-Agent Oral Regimens for Patients With Advanced Solid Tumor | NCT00495872 | Solid Tumors | Dasatinib Erlotinib Lapatinib Lenalidomide Sorafenib Sunitinib Valproic Acid | - | M.D. Anderson Cancer Center | |
| Pre-Surgical Sutent in Renal Cell Carcinoma (RCC) | NCT00715442 | Renal Cell Carc... | Sunitinib Nephrectomy | - | M.D. Anderson Cancer Center | |
| SU011248 for Platinum-Refractory Urothelial Cancer Evaluation Trial | NCT00578526 | Urothelial Canc... Bladder Cancer Adult | SU011248 Placebo | 18 Years - | AHS Cancer Control Alberta | |
| Study Of SU011248 Administered On A Continuous Daily Dosing Schedule In Patients With Gastrointestinal Stromal Tumor | NCT00137449 | Gastrointestina... | SU011248 | 18 Years - | Pfizer | |
| Sunitinib Malate in Refractory Germ Cell Tumors | NCT00912912 | Genitourinary D... | Sunitinib Malat... | 18 Years - | M.D. Anderson Cancer Center | |
| Study Of SU011248 Administered On A Continuous Daily Dosing Schedule In Patients With Gastrointestinal Stromal Tumor | NCT00137449 | Gastrointestina... | SU011248 | 18 Years - | Pfizer | |
| Phase II Study of Sunitinib Malate for Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma | NCT00400569 | Liposarcoma Leiomyosarcoma Fibrosarcoma Malignant Fibro... | Sunitinib Malat... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
